AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Gilead Sciences (GILD) is drawing attention this week as it presents new clinical results at both the European AIDS ...

Gilead Sciences and Arcus Biosciences’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to ...

Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The biopharma will aim to bolster its pipeline, with plans to present updated results for novel long-acting combination ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 20th European AIDS Conference (EACS) ...

Gilead Sciences Inc. (GILD) reached a notable milestone as its stock hit a 52-week high of $121.84, with InvestingPro data ...

GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...